Total Payments
$14,360
2024 Payments
$155.38
Companies
40
Transactions
815
Medicare Patients
10,456
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$13,626 (94.9%)
Travel$497.22 (3.5%)
Education$236.16 (1.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,626 | 797 | 94.9% |
| Travel and Lodging | $497.22 | 2 | 3.5% |
| Education | $236.16 | 16 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $2,028 | 165 | $0 (2023) |
| Amgen Inc. | $1,543 | 109 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $1,311 | 65 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $1,109 | 63 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,076 | 65 | $0 (2024) |
| BOSTON SCIENTIFIC CORPORATION | $902.30 | 9 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $899.02 | 56 | $0 (2023) |
| Amarin Pharma Inc. | $896.83 | 39 | $0 (2023) |
| PFIZER INC. | $842.08 | 66 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $812.30 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $155.38 | 7 | Novartis Pharmaceuticals Corporation ($34.33) |
| 2023 | $1,366 | 48 | Novartis Pharmaceuticals Corporation ($204.78) |
| 2022 | $1,647 | 90 | Amgen Inc. ($328.41) |
| 2021 | $1,656 | 95 | Janssen Pharmaceuticals, Inc ($453.92) |
| 2020 | $1,491 | 82 | Janssen Pharmaceuticals, Inc ($288.22) |
| 2019 | $2,042 | 155 | PFIZER INC. ($334.11) |
| 2018 | $3,384 | 173 | Boston Scientific Corporation ($869.10) |
| 2017 | $2,618 | 165 | Janssen Pharmaceuticals, Inc ($393.71) |
All Payment Transactions
815 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/25/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $34.33 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: Cardio-renal | ||||||
| 01/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/18/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 01/11/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $25.71 | General |
| Category: Genetic Disease | ||||||
| 01/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $30.31 | General |
| Category: DIABETES | ||||||
| 01/04/2024 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/07/2023 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $37.15 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/06/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/30/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $29.86 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/29/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $14.49 | General |
| Category: Cardiovascular | ||||||
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Cardiovascular | ||||||
| 11/09/2023 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: Genetic Disease | ||||||
| 11/09/2023 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug) | Food and Beverage | In-kind items and services | $14.14 | General |
| Category: Cardiology | ||||||
| 11/06/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/02/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/26/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/19/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $30.05 | General |
| Category: Not Applicable | ||||||
| 10/12/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.08 | General |
| Category: Cardiology | ||||||
| 10/11/2023 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $4.81 | General |
| Category: Cardiovascular | ||||||
| 10/03/2023 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Cardiology | ||||||
| 09/29/2023 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/27/2023 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $12.71 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 09/21/2023 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/14/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,978 | 2,891 | $678,675 | $227,578 |
| 2022 | 18 | 2,744 | 4,354 | $945,868 | $362,143 |
| 2021 | 18 | 2,836 | 4,716 | $1.0M | $415,193 |
| 2020 | 18 | 2,898 | 4,712 | $998,530 | $386,534 |
Total Patients
10,456
Total Services
16,673
Medicare Billing
$1.4M
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 761 | 1,430 | $386,100 | $136,382 | 35.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 321 | 341 | $150,040 | $53,371 | 35.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 107 | 107 | $37,450 | $13,119 | 35.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 418 | 489 | $48,900 | $5,500 | 11.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 74 | 81 | $15,390 | $4,405 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 25 | $9,500 | $3,721 | 39.2% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 11 | 11 | $6,050 | $2,402 | 39.7% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 39 | 74 | $4,810 | $1,681 | 35.0% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 11 | 84 | $3,528 | $1,649 | 46.7% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 32 | 46 | $3,772 | $1,308 | 34.7% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 56 | 57 | $2,850 | $1,052 | 36.9% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 14 | 36 | $3,420 | $956.80 | 28.0% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 42 | 42 | $2,310 | $847.47 | 36.7% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 11 | 11 | $1,705 | $602.00 | 35.3% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 56 | 57 | $2,850 | $580.80 | 20.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 760 | 1,681 | $394,950 | $161,582 | 40.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 360 | 366 | $164,220 | $58,595 | 35.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 138 | 138 | $123,096 | $43,392 | 35.3% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2022 | 138 | 275 | $45,925 | $24,278 | 52.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 157 | 157 | $54,414 | $19,716 | 36.2% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2022 | 73 | 292 | $26,280 | $14,267 | 54.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 175 | 202 | $33,036 | $12,491 | 37.8% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2022 | 144 | 144 | $22,178 | $7,631 | 34.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 455 | 585 | $43,440 | $6,529 | 15.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 29 | $9,508 | $3,682 | 38.7% |
About Dr. Daniel Ebenezer, M.D
Dr. Daniel Ebenezer, M.D is a Cardiovascular Disease healthcare provider based in Roseville, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508838541.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Ebenezer, M.D has received a total of $14,360 in payments from pharmaceutical and medical device companies, with $155.38 received in 2024. These payments were reported across 815 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($13,626).
As a Medicare-enrolled provider, Ebenezer has provided services to 10,456 Medicare beneficiaries, totaling 16,673 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Roseville, CA
- Active Since 02/03/2006
- Last Updated 03/10/2014
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1508838541
Products in Payments
- XARELTO (Drug) $2,028
- ELIQUIS (Drug) $1,314
- Repatha (Biological) $1,166
- ENTRESTO (Drug) $991.59
- MULTAQ (Drug) $906.36
- WATCHMAN (Device) $902.30
- Vascepa (Drug) $896.83
- FARXIGA (Drug) $642.02
- BRILINTA (Drug) $604.98
- PRADAXA (Drug) $490.31
- VERQUVO (Drug) $379.81
- Corlanor (Drug) $377.13
- JARDIANCE (Drug) $321.99
- NORTHERA (Drug) $231.94
- LifeVest (Device) $213.72
- PRALUENT (Drug) $202.53
- PRALUENT ALIROCUMAB INJECTION (Biological) $184.18
- HARMONY (Device) $181.46
- CAMZYOS (Drug) $180.99
- VYNDAQEL (Drug) $149.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Roseville
Dr. George Fehrenbacher, M.d, M.D
Cardiovascular Disease — Payments: $19,893
Cardiovascular Disease $19,893
Dr. Majid Alzagoum, M.d, M.D
Cardiovascular Disease — Payments: $16,653
Cardiovascular Disease $16,653
Hiroshi Yamasaki, Md, MD
Cardiovascular Disease — Payments: $16,222
Cardiovascular Disease $16,222
Dr. Nancy Mesiha, Md, MD
Cardiovascular Disease — Payments: $11,513
Cardiovascular Disease $11,513
Dr. Douglas Moore, D.o, D.O
Cardiovascular Disease — Payments: $9,608
Cardiovascular Disease $9,608
Dr. Subhi Sbahi, M.d, M.D
Cardiovascular Disease — Payments: $9,112
Cardiovascular Disease $9,112